[go: up one dir, main page]

WO2008006095A1 - Procédé de diagnostic d'un trouble du poids corporel ou d'une prédisposition à ce trouble chez un animal - Google Patents

Procédé de diagnostic d'un trouble du poids corporel ou d'une prédisposition à ce trouble chez un animal Download PDF

Info

Publication number
WO2008006095A1
WO2008006095A1 PCT/US2007/073008 US2007073008W WO2008006095A1 WO 2008006095 A1 WO2008006095 A1 WO 2008006095A1 US 2007073008 W US2007073008 W US 2007073008W WO 2008006095 A1 WO2008006095 A1 WO 2008006095A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
body weight
level
predisposition
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/073008
Other languages
English (en)
Inventor
Ryan Michael Yamka
Kim Gene Friesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hills Pet Nutrition Inc
Original Assignee
Hills Pet Nutrition Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hills Pet Nutrition Inc filed Critical Hills Pet Nutrition Inc
Publication of WO2008006095A1 publication Critical patent/WO2008006095A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • the present invention relates to methods of diagnosing a body weight condition or predisposition in an animal.
  • Obesity can be a risk factor for development of a variety of disorders or diseases.
  • Obesity for example, has been linked to heart disease, degenerative joint disease, diabetes and cancer, among other conditions. Further, an overweight animal may experience considerable problems through reduced mobility and decreased overall quality of life. Prevention of an overweight condition can have a lifelong impact and knowledge of the risk factors for development of such a condition can lead to improved prevention and treatment programs that optimize overall health.
  • the invention provides a method for diagnosing a body weight condition or predisposition thereto in an animal.
  • the method comprises determining observed level(s) of at least one biomarker in a tissue or biofluid sample from the animal and comparing the observed level(s) to reference level(s) for the biomarker, wherein the observed level(s) relative to the reference level(s) are individually or collectively indicative of the body weight condition or predisposition.
  • the method comprises (a) diagnosing a body weight condition or predisposition thereto by determining observed level(s) of at least one biomarker in a tissue or biofluid sample from the animal, and comparing the observed level(s) to reference level(s) for the biomarker; wherein the observed level(s) relative to the reference level(s) are individually or collectively indicative of the body weight condition or predisposition; and (b) identifying a regimen appropriate to the body weight condition or predisposition diagnosed.
  • the method comprises monitoring at least one biomarker in the animal over a period by determining, at each of a plurality of time points during the period, observed level(s) of the biomarker in a tissue or biofluid sample from the animal, and comparing the observed level(s) to reference level(s) for the biomarker; wherein onset is detected if, at any time point, the observed level(s) relative to the reference level(s) are individually or collectively indicative of the body weight condition or predisposition.
  • a method for assessing the efficacy of a regimen for managing a body weight condition or predisposition in an animal comprises monitoring at least one biomarker in the animal over a period during which the regimen is administered, by determining, at each of a plurality of time points during the period, observed level(s) of the biomarker in a tissue or biofluid sample from the animal, and comparing the observed level(s) to reference level(s) for the biomarker; wherein the observed level(s) relative to the reference level(s) are individually or collectively indicative of the efficacy of the regimen in managing the body weight condition or predisposition.
  • a kit comprising:
  • the animal is canine or feline.
  • the animal is up to about one year of age and the observed level(s) relative to the reference level(s) are individually or collectively indicative of predisposition to a body weight condition later in the animal's life.
  • the condition or predisposition is obesity or a propensity to gain weight.
  • the condition or predisposition increases the animal's risk for an overweight- related health disorder.
  • the overweight-related heath disorder is chosen from hyperlipidemia, dyslipidemia, insulin resistance, glucose intolerance, hepatic lipidosis, anesthetic complications, hypoadrenocorticism, hypothyroidism, diabetes mellitus, insulinoma, pituitary chromophobe adenoma, hypopituitarism, hypothalamic lesions, joint stress, musculoskeletal pain, dyspnea, hypertension, dystocia, exercise intolerance, heat intolerance, decreased immune function, degenerative joint and orthopedic diseases, cardiovascular diseases, transitional cell carcinomas, fatigue, sleep disorders, reproductive disorders, and combinations thereof.
  • the biomarker is chosen from glucose, GLP-I, ghrelin, and combinations thereof. Also, there is provided the above use wherein observed level(s) are determined for at least two biomarkers.
  • the tissue or biofluid sample is obtained when the animal is in a fasted state. Additionally, there is provided the above uses, wherein tissue or biofluid samples are obtained at a plurality of time points during a feeding cycle, including at least one preprandial time point and at least one postprandial time point. Also provided are the above uses, wherein the tissue or biofluid is whole blood, blood plasma or blood serum.
  • the above uses also include wherein the observed and reference levels are determined using one or more assays independently chosen from enzyme immunoassays, enzyme- linked immunosorbent assays, immunofluorescent assays, radioimmunoassays, western blot assays, biochemical assays, enzymatic assays, and colorimetric assays.
  • the animal is canine
  • the biomarker comprises glucose in serum
  • the observed body weight-adjusted serum glucose level in a fasted animal is at least about 10% lower than the body weight-adjusted reference level for a canine of normal weight, a predisposition of the animal to gain weight is diagnosed.
  • the animal is canine
  • the biomarker comprises GLP-I in serum
  • the observed body weight-adjusted serum GLP-I level in a fasted animal is at least about 20% lower than the body weight-adjusted reference level for a canine of normal weight, a predisposition of the animal to gain weight is diagnosed.
  • the animal is canine
  • the biomarker comprises ghrelin in serum
  • the observed body weight-adjusted serum ghrelin level in a fasted animal is at least about 20% lower than the body weight-adjusted reference level for a canine of normal weight, a predisposition of the animal to gain weight is diagnosed.
  • levels of certain biomarkers in a tissue or biofluid sample from an animal can be surprisingly effective in diagnosis of a body weight condition in the animal.
  • Levels of such biomarkers can fluctuate from a preprandial to a postprandial state.
  • individual animals with different body weight conditions e.g., lean and obese animals, show differences in the form and/or degree of such fluctuation, as well as in absolute levels of the biomarkers when in a fasted state.
  • Profiles of one or more biomarkers therefore, can be indicative of a body weight condition. Further, such profiles are indicative of a predisposition to a body weight condition, even where that condition is not yet expressed.
  • Biomarkers of interest herein are those for which an observed level relative to a reference level is indicative of a body weight condition or predisposition.
  • a reference level can be established from samples obtained from healthy animals of normal body weight, or can be a published value.
  • reference levels are established for animals of the same species and, if possible, breed or breed type. Further, it is generally preferable that reference levels are established for animals of similar age group to the animal. In this case, an observed level substantially different from (e.g., higher or lower than) the reference level can be indicative of a body weight condition or predisposition. Such a difference can be, but is not necessarily, statistically significant.
  • a reference level can be established for animals known to have a particular body weight condition or predisposition; an observed level similar to the reference level can in this case be indicative of the condition or predisposition.
  • the level of a biomarker can provide information about underlying genetic, biochemical or physiological factors, mechanisms or pathways associated with a particular existing body weight condition (e.g., normal weight, overweight, obese), but is not necessarily informative in this way. In some cases, a statistical correlation between a level of a biomarker and an observed body weight condition or predisposition can suffice for practice of the invention. However, where the biomarker provides information of genetic, biochemical or physiological relevance, advantages over traditional methods relying solely on physical measurements related to body weight can be especially great.
  • the animal can be human or non-human. In various embodiments, the animal is a vertebrate, for example a fish, a bird, a reptile or a mammal. Illustratively among mammals, the animal can be a member of the order Can ⁇ vora, including without limitation canine and feline species. In some embodiments, the animal is a mammal.
  • the animal is a companion animal.
  • a "companion animal” herein is an individual animal of any species kept by a human caregiver as a pet, or any individual animal of a variety of species that have been widely domesticated as pets, including dogs (Cams familiaris) and cats (Felis domes ticus), whether or not the individual animal is kept solely or partly for companionship.
  • “companion animals” herein include working dogs, farm cats kept for rodent control, etc., as well as pet dogs and cats.
  • the animal is a canine, hi other embodiments, the animal is a feline.
  • a body weight condition diagnosed according to the invention can be an underweight, normal weight or overweight, including obese, condition.
  • Body weight is generally not simply a matter of weight alone, but is usually associated with quantity or percentage of body fat. See for example Burkholder & Toll (2000) in Hand et al. (eds.), Small Animal Clinical Nutrition, 4th Edition, Chapter 13, pp 402-430.
  • a "body weight predisposition” herein refers to an animal's proneness (i.e., propensity) for gaining, losing, or maintaining body weight and/or undergoing concomitant changes in health or other physiological conditions.
  • body weight predispositions include a propensity, or lack thereof, to gain weight and a predisposition to obesity.
  • a body weight predisposition is diagnosed by a method of the invention while the animal is young, for example, in the case of a canine or feline, up to about one year of age.
  • An overweight or obese condition can be an associative cause or exacerbating factor for a number of diseases and disorders including, for example, metabolic alterations, endocrinopathies, functional alterations, degenerative joint and orthopedic diseases, cardiovascular diseases, cancers, sleep disorders, reproductive disorders, and combinations thereof.
  • An overweight condition also can cause considerable problems through reduced mobility or decreased quality of life.
  • a body weight condition or predisposition diagnosed by practice of the invention is one that increases the animal's risk for an overweight-related health disorder.
  • Such overweight-related heath disorders illustratively include hyperlipidemia, dyslipidemia, insulin resistance, glucose intolerance, hepatic lipidosis, anesthetic complications, hyperadrenocorticism, hypothyroidism, diabetes mellitus, insulinoma, pituitary chromophobe adenoma, hypopituitarism, hypothalamic lesions, joint stress, musculoskeletal pain, dyspnea, hypertension, dystocia, exercise intolerance, heat intolerance, decreased immune function, degenerative joint and orthopedic diseases, cardiovascular diseases, transitional cell carcinomas, fatigue, sleep disorders, reproductive disorders, and combinations thereof.
  • biomarker means a substance that can be quantitatively identified in a tissue or biofluid sample and that provides a correlation to a particular phenotype or physiological condition.
  • a biomarker can be a cytokine, e.g., an inflammatory cytokine; a peptide or protein, e.g., peptide YY, neuropeptide Y, glucagon-like peptide 1 (GLP-I), ghrelin; a nucleic acid, e.g., an mRNA transcript corresponding to a peptide or protein biomarker, a biochemical metabolite, e.g., glucose; a neurotransmitter; an agonist; or an antagonist, hi various embodiments, level(s) of at least one of the following biomarkers are determined: glucose, GLP-I, ghrelin, leptin, adiponectin, resistin, resistinlike molecules, and insulin. Particularly
  • Diagnosis of a body weight condition or predisposition by the method of the invention can involve determination of more than one biomarker.
  • a single biomarker can be indicative of the body weight condition or predisposition; in other cases, a biomarker profile, comprising levels of two or more biomarkers, is collectively indicative of the condition or predisposition.
  • Any tissue or biofluid sample can be a source of biomarkers of interest. However, in most cases biofluid samples that can be obtained with minimal invasion are preferred. Biofluids illustratively include whole blood, blood serum, blood plasma, cerebrospinal fluid, crevicular fluid, urine, lymph fluid, intramuscular fluid, nasal secretion and saliva.
  • a level of a biomarker can be determined using assays known in the art.
  • An assay can, but need not, be a commercially available assay.
  • an assay is chosen based on the type of biomarker and the type of sample.
  • a commercially available monoclonal-based immunoassay utilizing monoclonal antibodies reactive to one or more epitopes on polypeptides or a competitive binding assay can be used for determining a blood serum level of a protein biomarker such as, for example, GLP-I or ghrelin; and an assay based on a ferricyanide, hexokinase, or glucose oxidase procedure can be used for determining a blood serum level of glucose.
  • observed and/or reference levels are determined using one or more assays independently chosen from enzyme immunoassays (ElA), enzyme-linked immunosorbent assays (ELISA), immunofluorescent assays (IFA), radioimmunoassays (RIA), western blot assays, biochemical assays, enzymatic assays, and colorimetric assays.
  • assays independently chosen from enzyme immunoassays (ElA), enzyme-linked immunosorbent assays (ELISA), immunofluorescent assays (IFA), radioimmunoassays (RIA), western blot assays, biochemical assays, enzymatic assays, and colorimetric assays.
  • a tissue or biofluid sample can be collected, for example, at a point of care facility, i.e., a place where an animal can be seen by a health care practitioner (e.g., medical doctor, veterinarian, medical assistant, physician's assistant, nurse, etc.) for evaluation and diagnosis.
  • a point of care facility i.e., a place where an animal can be seen by a health care practitioner (e.g., medical doctor, veterinarian, medical assistant, physician's assistant, nurse, etc.) for evaluation and diagnosis.
  • a point of care facility include a hospital, office of a physician or veterinarian, and veterinary clinic.
  • a sample can be collected at the animal's home, farm, stable or barracks where the animal is kept.
  • Analysis of the sample for the one or more biomarkers of interest can be done at the place, e.g., point of care facility, where the sample is taken.
  • a kit as described herein can be used in such analysis.
  • the sample can be sent to a secondary facility.
  • the te ⁇ n "secondary facility" means a laboratory such as a commercial testing laboratory where clinical samples are evaluated, and can be off-site (i.e., at a different location) from a point of care facility.
  • comparing the observed level(s) to reference level(s) of the one or more biomarkers is performed at a point of care facility or a secondary facility.
  • a sample is taken at a single time point, this can be at any stage of the animal's feeding cycle, for example immediately before a meal (preprandial) or at a suitable interval after a meal (postprandial).
  • diagnosis is to be based on a single sample, that such sample be taken when the animal is in a fasting state, for example at a preprandial time point.
  • samples are taken at a plurality of time points during the feeding cycle.
  • at least one (typically just one) preprandial sample and at least one (typically more than one) postprandial sample can be taken.
  • Suitable time points are illustratively 0 (preprandial), 10, 30,
  • Biomarker levels in a sample can be unadjusted, or adjusted for body weight of the animal.
  • Unadjusted levels can be expressed in weight/volume concentration units such as mg/L, ⁇ g/L or ng/L, or molar concentration units such as ⁇ mol/L, nmol/L or pmol/L.
  • Adjusted levels can be expressed in similar units, but with body weight (BW) as a divisor, e.g., mg/L/kg BW, pmol/L/kg BW, etc.
  • the animal is canine and the biomarker comprises glucose in serum.
  • an observed body weight- adjusted serum glucose level in a fasted animal at least about 10% lower than the body weight-adjusted reference level for a canine of normal weight is indicative of a predisposition of the animal to gain weight.
  • the animal is canine and the biomarker comprises GLP- 1 in serum.
  • an observed body weight-adjusted serum GLP-I level in a fasted animal at least about 20% lower than the body weight-adjusted reference level for a canine of normal weight is indicative of a predisposition of the animal to gain weight.
  • the animal is canine and the biomarker comprises ghrelin in serum.
  • the biomarker comprises ghrelin in serum.
  • an observed body weight-adjusted serum ghrelin level in a fasted animal at least about 20% lower than the body weight-adjusted reference level for a canine of normal weight is indicative of a predisposition of the animal to gain weight.
  • a regimen appropriate to the condition or predisposition can be selected.
  • the regimen can be selected by the animal or the animal's caregiver based on information communicated by any suitable communication means, or can be prescribed by a health care professional.
  • the regimen can comprise one or more of diet, exercise, and medication.
  • a regimen comprises a composition for consumption by the animal.
  • a composition can be a nutritional composition, such as a food composition, a supplement, a treat or a toy, it being noted that some, but not all, supplements, treats and toys are themselves food compositions.
  • Food compositions can be, for example, ingested by an animal or administered to an animal by feeding. Where the animal is a companion animal, a food composition useful in the method of the invention is typically one that is nutritionally adapted for feeding to such an animal (referred to herein as a "pet food”) and is appropriate for the body weight condition or predisposition diagnosed.
  • Pet foods can be more particularly adapted to the special nutritional needs of canines or felines, or to certain subpopulatio ⁇ s thereof such as large-breed dogs, puppies or kittens, young dogs or cats, adult dogs or cats, senior dogs or cats, and geriatric dogs or cats.
  • a food composition forming part of a regimen can be one providing a substantially nutritionally complete diet for the animal.
  • a "nutritionally complete diet” is a diet that includes sufficient nutrients for maintenance of normal health of a healthy animal on the diet.
  • the composition can be a supplement, i.e., a composition used with another food composition to improve the nutritive balance or performance of the diet as a whole.
  • Such supplements include food compositions that are fed undiluted as a supplement to other foods, offered free choice with other parts of an animal's ration that are separately available to the animal, or diluted and mixed with an animal's regular food to produce a substantially nutritionally complete diet.
  • Supplements can alternatively be in a form other than a food composition, for example in a pharmaceutical-like dosage form including, for example, powders, liquids, syrups, pills, etc.
  • the composition can be a treat. Treats include, for example, compositions given to an animal as a reward or to entice the animal to eat during a non-mealtime. Treats for dogs that are food compositions having at least some nutritional value include, for example, dog biscuits. Treats can alternatively be substantially non-nutritional.
  • a composition forming part of a regimen can itself form a treat, be coated onto an existing treat, or both.
  • the composition can be a toy adapted for oral use by an animal.
  • Toys include, for example, chewable toys, such as artificial bones for dogs.
  • a composition useful herein can form a coating on the surface of a toy or on the surface of a component of a toy, be incorporated partially or fully throughout the toy, or both.
  • suitable toys is currently marketed, including partially consumable toys (e.g., toys comprising plastic components) and fully consumable toys (e.g., rawhides and various artificial bones).
  • Toys are available for human and non-human use, particularly for companion, farm, and zoo animal use, and more particularly for dog, cat, or bird use.
  • a regimen comprises a form of exercise.
  • Exercise can take any form suitable for the animal and appropriate for the body weight condition or predisposition diagnosed.
  • exercise can include without limitation walking, jogging or running.
  • the regimen can be continued at a frequency or for a period of time as is necessary or appropriate for the body weight condition or predisposition.
  • a regimen can continue for at least about 1 month, at least about 2 months, at least about 6 months, at least about 1 year, or for some other period of time as may be determined necessary or appropriate, for example by a veterinarian or other health care professional.
  • the invention also provides a method for detecting onset of a body weight condition or predisposition in an animal.
  • a method for detecting onset of a body weight condition or predisposition in an animal According to this method, at least one biomarker in the animal is monitored over a period, and onset is detected if. at any time point during that period, the observed level(s) relative to the reference level(s) of the biomarker are individually or collectively indicative of the body weight condition or predisposition.
  • Such a method optionally further comprises monitoring the animal's body weight during at least part of the period.
  • Any appropriate technique for determining body weight can be used, including without limitation weighing, assessment of relative body weight (RBW), assessment of body condition score (BCS), morphometry, and combinations thereof.
  • Additional useful information relating to body weight can optionally be obtained by techniques such as magnetic resonance imaging (MRI), computerized tomography (CT), neutron activation, hydrodensitometry, total body water by isotope dilution, total body potassium, ultrasound, bioelectrical impedance, radiograph, sonograph, dual energy x-ray absorptiometry (DEXA), or combinations thereof.
  • MRI magnetic resonance imaging
  • CT computerized tomography
  • DEXA dual energy x-ray absorptiometry
  • Monitoring of the biomarker, and optionally of body weight and/or other related parameters can be performed at any convenient interval, for example at about hourly, twice daily, daily, twice weekly, weekly, monthly, bimonthly, twice yearly or yearly intervals.
  • Monitoring of the biomarker can also provide a useful method for assessing the efficacy of a regimen for managing a body weight condition or predisposition in an animal. According to this method, the biomarker, and optionally body weight and/or other related parameters, are monitored over a period during which the regimen is administered. The observed level(s) relative to the reference level(s) of the biomarker can be individually or collectively indicative of the efficacy of the regimen in managing the body weight condition or predisposition.
  • kits suitable for use according to any of the methods described herein.
  • a kit comprises one or more reagents for detecting observed level(s) of at least one biomarker in a tissue or biofluid sample from an animal; and one or more user-accessible media carrying information that comprises (i) reference level(s) of the biomarker; and (ii) an algorithm that compares the observed level(s) to the reference level(s).
  • the observed level(s) relative to the reference level(s) are individually or collectively indicative of a body weight condition or predisposition in the animal.
  • "User-accessible" media herein include all media, such as paper, disk, memory chip, card, computer or network, on which instructions, information, an algorithm and/or data can be retrievably contained or stored.
  • the algorithm is typically a software algorithm.
  • the kit is optionally self-contained so as not to require laboratory equipment.
  • the kit further comprises a tissue or biofluid sample collection device.
  • the kit can employ one or more of a variety of assays for determining a level of a biomarker, including the assays listed above. Standards and standard additions can be included and used for calibration in quantifying the level of a biomarker in a sample, using well known techniques.
  • the one or more reagents of the kit comprise a reporter moiety or label.
  • the reporter moiety or label can illustratively comprise biotin, a chromogenic agent, a luminescent or chemiluminescent, a cofactor, an enzyme, a fluorescent agent, an inhibitor, a metal or magnetic particle, a radionuclide, a substrate or a combination thereof, and can be detected using methods known in the art.
  • such methods include without limitation spectroscopic methods used to detect dyes (including, for example, colorimetric detection of products of enzyme reactions), luminescent groups and fluorescent groups; detection of enzyme reporter groups by addition of a substrate, followed by spectroscopic, spectrophotometric or other analysis of reaction products; scintillation counting or autoradiographic methods for radioactive groups; and Raman scattering techniques for metal nanoparticles (e.g., gold nanoparticles).
  • the one or more reagents of a kit can comprise at least one antibody, for example a polyclonal or monoclonal antibody.
  • the antibody can be immobilized on a solid support.
  • an ELISA can be utilized to determine a level of a biomarker in a sample.
  • the ELISA can involve coupling an antibody onto a solid support such as a polymer.
  • a sample comprising a biomarker can be introduced and the biomarker allowed to interact with the antibody, whereupon a signal (e.g., chromogenic signal) generating process can be performed to create an optically detectable signal.
  • a signal e.g., chromogenic signal
  • the kit comprises a first antibody that specifically binds to the biomarker in the sample, and a second antibody that specifically binds to the resulting complex of the first antibody and the biomarker.
  • the second antibody can be immobilized to a solid support. For example, upon binding of the second antibody to the first antibody/biomarker complex, the second antibody can trigger a reaction and, for example, result in a detectable color change.
  • a variety of labels and conjugation techniques are known by those skilled in the arts. Techniques for producing labeled hybridization or PCR probes for detection and quantification of nucleic acid sequences include oligo-labeling, nick translation, end-labeling and PCR amplification using a labeled nucleotide.
  • the coding sequence of a biomarker, or any portion thereof may be cloned into a vector for production of an mRNA probe.
  • a vector for production of an mRNA probe Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6, and labeled nucleotides.
  • the kit optionally further comprises means for communicating information comprising one or more of (a) a diagnosis of a body weight condition or predisposition as indicated by the observed level(s) relative to the reference level(s) of the biomarker; and (b) a suggested or prescribed regimen appropriate to the diagnosis.
  • the communicating means can be attached to or enclosed in a package containing other elements of the kit.
  • Any suitable form of communicating means can be employed, for example a document such as a label, brochure, advertisement or package insert, a computer-readable digital or optical medium such as a diskette or CD, an audio presentation, for example on an audiotape or CD, or a visual presentation, for example on a videotape or DVD.
  • the communicating means can refer to further information located elsewhere, such as on a website.
  • Such a communicating means comprising for example a document such as a label, brochure, advertisement or package insert, a computer-readable digital or optical medium such as a diskette or CD, an audio presentation, for example on an audiotape or CD, a visual presentation, for example on a videotape or DVD, and/or one or more pages on a website, is itself a still further embodiment of the invention.
  • Average body weight for lean-prone dogs are 12.06 kg and for obese-prone dogs 16.59 kg.
  • the dogs are fed, once daily for four days, a maintenance food formulated to meet or exceed nutritional requirements for maintenance of body weight (BW).
  • BW body weight
  • blood serum samples are taken prior to feeding (preprandial, time 0), and 10, 60, 120, and 360 minutes after feeding (postprandial).
  • the samples are analyzed for insulin, triglycerides, glucose, GLP-I, and ghrelin concentrations using standard procedures found, for example, in laboratory manuals such as Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, 3rd ed.
  • serum triglyceride concentrations do not differ substantially between lean-prone and obese-prone dogs (Table 2).
  • Serum concentrations of glucose (Table 3), GLP-I (Table 4), and ghrelin (Table 5) levels differ substantially between lean-prone and obese- prone dogs at most or all of the six sampling times).
  • the data show the utility of biomarkers, in particular serum glucose, GLP-I and ghrelin levels, to differentiate animals having lean and obese predisposition.
  • Serum is analyzed for chemistry screens, obesity markers, thyroid markers and arthritis markers.
  • Chemistry screens are preformed at the Hill's Pet Nutrition Center (Topeka, KS).
  • Insulin analysis is performed by Michigan State University (Lansing, MI).
  • Thyroxine, thyroid stimulating hormone, glucagon like protein-1 , insulin like growth factor-1, ghrelin, leptin, angiotensin I and II, c-reactive protein, high density lipoprotein 1 and 2, low density lipoprotein, very low density lipoprotein, chylomicron, testosterone, estradiol, Cortisol, osteocalcin, amino terminal crosslink protein, type 2 cartilage synthesis and cartilage oligometric protein are performed by MD Biosciences, Inc. (St. Paul, MN).
  • Body Condition Score 2.53 4.70 0.08 ⁇ 0.01 Body Weight, kg 1 1.18 17.26 0.42 ⁇ 0.01 Glucose. mg/dL 84.10 93.20 2.00 ⁇ 0.01 Average Average Lean Overweight Standard Lean vs.
  • Triglycerides mg/dL 91.87 242.77 56.53 0.06
  • Thyroxine ⁇ g/dL 1.71 2.02 0.11 0.05
  • Thyroid Stimulating Hormone ng/mL 0.19 0.21 0.02 NS
  • Non-esterified fatty acids mM 0.75 0.80 0.07 NS
  • Chylomicrons % of total 0.43 0.92 0.20 0.08
  • Triglycerides mg/dL 68.47 251.00 79.95 NS
  • Angiotensin I ng/mL 0.60 0.66 0.07 NS
  • Non-esterified fatty acids mM 0.62 0.73 0.10 NS
  • Chylomicrons (% of Total) 0.20 0.87 0.28 0.09 Female
  • Insulin pmol/L 75.60 146.29 20.14 0.02
  • Triglycerides mg/dL 1 15.27 234.53 79.95 NS
  • Angiotensin I ng/mL 0.62 0.65 0.07 NS
  • Chylomicrons % of total 0.65 0.97 0.28 NS
  • Average body condition scores are 4.7 and 2.5 for the overweight and lean groups, respectively.
  • Average body weights are 11.2 and 17.3 kg for the overweight and lean groups, respectively.
  • Serum is analyzed for chemistry screens, obesity markers, thyroid markers and arthritis markers.
  • EXAMPLE 3 Materials and Methods [0081 ] Thirty lean and thirty overweight cats are identified for this study. Cats with a body condition score (BCS) of 4 or 5 are classified as obese/overweight for purposes of this study (on a scale of 1 through 5 where 1 equals thin and 5 equals obese). Cats with a BCS less than 3 are classified as lean. Animals are weighed, given a body condition score and a blood sample is drawn. Serum is harvested and stored at -20°C in 1 mL aliquots.
  • BCS body condition score
  • Serum is analyzed for chemistry screens, obesity markers, thyroid markers and arthritis markers.
  • Chemistry screens are performed at the Hill's Pet Nutrition Center (Topeka, KS).
  • Insulin analysis is performed by Michigan State University (Lansing, MI).
  • Thyroxine, thyroid stimulating hormone, ghrelin, leptin, angiotensin I and II, osteocalcin, amino terminal crosslink protein, bone-specific alkaline phosphatase and carboxy terminal crosslink telopeptide are performed by MD Biosciences, Inc. (St. Paul, MN).
  • Triglycerides mg/dL 38.8 56.3 6.1 0.05
  • Average body condition scores are 4.2 and 2.5 for the overweight and lean groups, respectively.
  • Average body weights are 5.8 ⁇ 0.2 and 3.2 ⁇ 0.2 kg for the overweight and lean groups, respectively.
  • Serum is analyzed for chemistry screens, obesity markers, thyroid markers and arthritis markers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé de diagnostic d'un trouble du poids corporel ou d'une prédisposition à un trouble du poids corporel chez un animal, ledit procédé comprenant la détermination d'un ou de plusieurs niveaux observés d'au moins un marqueur biologique dans un échantillon de tissu ou de fluide biologique issu de l'animal et la comparaison du ou des niveaux observés avec un ou des niveaux de référence pour le marqueur biologique. Selon l'invention, le ou les niveaux observés en relation avec le ou les niveaux de référence sont individuellement ou collectivement indicateurs du trouble du poids corporel ou de la prédisposition.
PCT/US2007/073008 2006-07-07 2007-07-09 Procédé de diagnostic d'un trouble du poids corporel ou d'une prédisposition à ce trouble chez un animal Ceased WO2008006095A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81929806P 2006-07-07 2006-07-07
US60/819,298 2006-07-07

Publications (1)

Publication Number Publication Date
WO2008006095A1 true WO2008006095A1 (fr) 2008-01-10

Family

ID=38669547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073008 Ceased WO2008006095A1 (fr) 2006-07-07 2007-07-09 Procédé de diagnostic d'un trouble du poids corporel ou d'une prédisposition à ce trouble chez un animal

Country Status (1)

Country Link
WO (1) WO2008006095A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104569419A (zh) * 2014-09-23 2015-04-29 范列英 一种检测人血液glp-1总含量的化学发光免疫分析法试剂盒
CN112394102A (zh) * 2020-11-05 2021-02-23 上海交通大学医学院附属瑞金医院 一种检测垂体功能减退症的标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233393A1 (en) * 2004-02-27 2005-10-20 Wynne-Edwards Katherine E Dynamic hormone index as a biomarker for disease
WO2006063213A2 (fr) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Proteine serum amyloide a utilisee contre l'inflammation et l'obesite

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233393A1 (en) * 2004-02-27 2005-10-20 Wynne-Edwards Katherine E Dynamic hormone index as a biomarker for disease
WO2006063213A2 (fr) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Proteine serum amyloide a utilisee contre l'inflammation et l'obesite

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
APPLETON D J ET AL: "Plasma leptin concentrations in cats: reference range, effect of weight gain and relationship with adiposity as measured by dual energy X-ray absorptiometry.", JOURNAL OF FELINE MEDICINE AND SURGERY DEC 2000, vol. 2, no. 4, December 2000 (2000-12-01), pages 191 - 199, XP009087672, ISSN: 1098-612X *
DAMINET S ET AL: "Evaluation of thyroid function in obese dogs and in dogs undergoing a weight loss protocol.", JOURNAL OF VETERINARY MEDICINE SERIES A, vol. 50, no. 4, May 2003 (2003-05-01), pages 213 - 218, XP002445146, ISSN: 0931-184X *
JEUSETTE ISABELLE C ET AL: "Influence of obesity on plasma lipid and lipoprotein concentrations in dogs", AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 66, no. 1, January 2005 (2005-01-01), pages 81 - 86, XP009086366, ISSN: 0002-9645 *
KIRK C A ET AL: "Diagnosis of naturally acquired type-I and type-II diabetes mellitus in cats", AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 54, no. 3, 1993, pages 463 - 467, XP009087685, ISSN: 0002-9645 *
SAGAWA MAYUMI M ET AL: "Correlation between plasma leptin concentration and body fat content in dogs", AMERICAN JOURNAL OF VETERINARY RESEARCH, XX, XX, vol. 63, no. 1, January 2002 (2002-01-01), pages 7 - 10, XP009086365, ISSN: 0002-9645 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104569419A (zh) * 2014-09-23 2015-04-29 范列英 一种检测人血液glp-1总含量的化学发光免疫分析法试剂盒
CN112394102A (zh) * 2020-11-05 2021-02-23 上海交通大学医学院附属瑞金医院 一种检测垂体功能减退症的标志物及其应用
CN112394102B (zh) * 2020-11-05 2023-05-26 上海交通大学医学院附属瑞金医院 一种检测垂体功能减退症的标志物及其应用

Similar Documents

Publication Publication Date Title
Sink et al. Validation, use, and disadvantages of enzyme-linked immunosorbent assay kits for detection of cortisol in channel catfish, largemouth bass, red pacu, and golden shiners
Hiden et al. Insulin control of placental gene expression shifts from mother to foetus over the course of pregnancy
Tvarijonaviciute et al. Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome
Xenoulis et al. Investigation of hypertriglyceridemia in healthy Miniature Schnauzers
CA2743714C (fr) Test diagnostique nutrigenomique de sensibilite a des aliments en plusieurs etapes sur des animaux
Jarcho et al. Digestive efficiency mediated by serum calcium predicts bone mineral density in the common marmoset (Callithrix jacchus)
Travail et al. Assessment of the likelihood of hypothyroidism in dogs diagnosed with and treated for hypothyroidism at primary care practices: 102 cases (2016‐2021)
Ragno et al. Morphometric, metabolic, and inflammatory markers across a cohort of client-owned horses and ponies on the insulin dysregulation spectrum
Yu et al. Assessment of serum symmetric dimethylarginine and creatinine concentrations in hyperthyroid cats before and after a fixed dose of orally administered radioiodine
Verkest et al. Association of postprandial serum triglyceride concentration and serum canine pancreatic lipase immunoreactivity in overweight and obese dogs
US20090123951A1 (en) Method Of Diagnosing A Body Weight Condition Or Predisposition
Contreras-Aguilar et al. Changes in salivary analytes in cows due to the in vitro presence of feed
Kovacikova et al. Canonical Correlation of Milk Composition Parameters and Blood Biomarkers in High-Producing Dairy Cows During Different Lactation Stages
Black et al. Longitudinal increases in adiposity contribute to worsening adipokine profile over time in Mexican Americans
WO2008006095A1 (fr) Procédé de diagnostic d'un trouble du poids corporel ou d'une prédisposition à ce trouble chez un animal
Alberghina et al. Serum serotonin (5-HT) in dogs (Canis familiaris): Preanalytical factors and analytical procedure for use of reference values in behavioral medicine
Camassa et al. Tartrate-resistant acid phosphate as biomarker of bone turnover over the lifespan and different physiologic stages in sheep
Heilmann et al. Effect of gastric acid-suppressive therapy and biological variation of serum gastrin concentrations in dogs with chronic enteropathies
Ball et al. Next generation diet formulation: true metabolic availability of amino acids in diets for pigs.
Fredholm et al. Evaluation of precision and establishment of reference ranges for plasma thyroxine using a point-of-care analyzer in healthy guinea pigs (Cavia porcellus)
WO2007079386A2 (fr) Procédé de diagnostic d'une condition ou d'une prédisposition de poids d'un corps
Kriström et al. Impact of blood tube additives and timing of sampling on blood taurine concentrations in clinically healthy dogs
Miceli et al. Increased insulin-like growth factor 1 concentrations in a population of non-diabetic cats with overweight/obesity
Stockman et al. Cystine and amino acid concentrations in the urine of pet ferrets (Mustela putorius furo)
US7687238B2 (en) Method for evaluating kidney function in a feline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812703

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07812703

Country of ref document: EP

Kind code of ref document: A1